



The NKI Informer



A newsletter of the Nathan S. Kline Institute for Psychiatric Research

Donald C. Goff, MD, Director
Antonio Convit, MD, Deputy Director
Thomas O'Hara, MBA, Deputy Director, Institute Administration

July / August, 2015

Stuart Moss, MLS, Editor

CRYSTAL FULLER LEWIS *Seeking Social Solutions*



Crystal Fuller Lewis, PhD joined NKI on June 1, and heads the renewed Division of Social Solutions and Services Research (formerly Division of Statistics and Services Research). At the same time, she joined the Department of Psychiatry at NYU School

of Medicine as a Research Associate Professor. Dr. Lewis earned her PhD in Epidemiology from Johns Hopkins University, Bloomberg School of Public Health, and comes to NKI from the Department of Epidemiology, Mailman School of Public Health at Columbia University where she sustained a successful NIH-funded research program over the past 15 years, focused on substance use and the social and medical-related disparities experienced by those at risk and/or heavily burdened by substance use in NYC. Her primary content areas have included various forms of stigma, lack of social support, incarceration, unstable housing, mental illness, and both chronic and infectious diseases typically faced by our most vulnerable communities.

Dr. Lewis's research portfolio includes the design, conduct, and analysis of community-based studies, particularly structural and multilevel interventions that consider many of these life circumstances. For example, her current research involves the use of pharmacies in low-income communities as a structural approach to increasing access to biomedical HIV prevention services and medical care through the use of a technology-supported pharmacist-clinician partnership providing co-managed patient care (*iPEPcare*). Another structural approach to increase access to services included "packaging" HIV testing services with

chronic disease screening services (cholesterol, blood pressure, and glucose) in a pharmacy setting which resulted in increased uptake in HIV testing specifically among those who expressed internalized stigma (compared to those offered HIV testing alone). Dr. Lewis most recently expanded her research expertise into the use of internet and mobile technologies to help connect persons heavily involved in substance use to substance use prevention, treatment, and relevant social/medical services (*WebHealth4Us.com*).

Why NKI?

In studying the epidemiology of substance use and designing interventions to increase access to prevention, care and services, it is clear that other forms of mental illness – including depression anxiety, and severe psychiatric conditions – are all-too-often related to the problem of substance use. New York State has reached a critical time in the design of mental health services which can now be delivered with attention to the many social and structural challenges faced by the most vulnerable populations. After 15 years of independent research and publishing results of successful interventions, moving a step closer to policy and policy makers is an opportunity to conduct research within an arena where there is a much higher potential for impact than within a pure academic setting.

New Vision

While there is much discussion about the need for better care and new approaches to the ways in which services are delivered, there are still obvious gaps in this delivery system. It is my goal that NKI, through our new Division of Social Solutions and Services Research, will be recognized as the leader in research and evaluation that directly impacts the delivery of mental health services to underserved citizens across New York State.

My vision for the Division of Social Solutions and Services Research is to expand beyond the clinic walls to solve the persistent problem of disparities in access to both prevention and treatment services, such that wellness and recovery can be realized for all New Yorkers. And, due to new national and state policy reforms, connecting highest need communities to prevention, wellness, and recovery is a high priority for the Office of Mental Health as well as for NKI.

Aligned with this vision, OMH has increased its emphasis on the redesign of our mental health care system by (1) shifting focus from institutional settings to community-based care, and (2) supporting integration of medical and mental health care. Several initiatives to achieve these objectives are currently underway, creating a need for rigorous evaluation of their impact, particularly among the most vulnerable, high risk communities.

Our Approach

Our research efforts will focus on long-standing individual and structural barriers to prevention, wellness, and recovery that have been most difficult to address and typically include unstable housing, criminal justice involvement, and substance use dependence. These factors are, in turn, intertwined with race and ethnicity, income, immigration status, language barriers, aging, and culturally-based factors including various forms of stigma and discrimination that often accompany these challenging life circumstances. Testing innovative approaches (such as use of mental health peer advocates) to improve quality service outcomes and using robust epidemiologic and services research methods are vital for achieving successful translation, implementation, and sustainability. At NKI, this opportunity exists given the energetic research team in the Division. Our team will be engaged in investigating creative solutions operating at both individual and structural levels to optimize effective and efficient delivery of mental health care.

GRANTS AND FUNDING

FUNDING OPPORTUNITY



Blas Frangione Young Investigator Research Grant

The Blas Frangione Foundation is now accepting applications for a research grant for the academic year 2016-2017 at New York University. This grant promotes the work of outstanding young investigators establishing their independence in the field of neuroscience and provides support during a critical period of career development.

AMOUNT: \$50,000 to be used for research purposes.

CRITERIA: Applications are encouraged from early career basic, translational and clinical scientists currently active in research within the field of neuroscience, brain function, brain aging, Alzheimer's disease and related neurodegenerative diseases. Applicants can have any level of faculty appointment up through assistant professor. The research presented must be original and innovative and focus on advancing the understanding of the brain and application of new scientific knowledge to develop improved disease treatments and cures. We welcome applications from a diverse array of departments whose research is linked to brain study, specifically but not limited to neurology, psychiatry, anesthesiology, neurosurgery, radiology, geriatrics, child studies, etc.

APPLICATION INFORMATION: A project proposal following the RO3 NIH format, along with a biosketch, should be submitted by October 1, 2015 to Camy Sleeman at camy.sleeman@nyumc.org. The awardee will be notified on December 1, 2015. Anticipated start date of award is January 1, 2016. For specific information about the application, please contact Dr. Blas Frangione

at blas.frangione@nyumc.org. The Foundation committee will be responsible for the review of applications and making the final decision.

PROGRAM INFORMATION: The goal of the Blas Frangione Foundation, established in 2009 by Blas Frangione, MD, PhD, Professor of Pathology and Psychiatry, is to support research relevant to neuroscience, brain aging and neurodegenerative diseases.

FROM AROUND THE INSTITUTE

KUDOS

MERIT Award to Regina Sullivan

Regina Sullivan, PhD (Emotional Brain Institute) has received a MERIT Award from the National Institute of Child Health and Development (NICHD). MERIT stands for Method to Extend Research In Time. Since 1987, these awards have been made to investigators who have demonstrated superior competence and outstanding productivity during their previous research experience. The purpose of the award is to provide such investigators with long-term, stable support to foster their continued creativity. Read more about Dr. Sullivan's research [here](#).

Zaven Khachaturian Award to Dr. Nixon

Ralph A. Nixon, MD, PhD, Director of the [Center for Dementia Research](#), was recognized by the Alzheimer's Association at the [AAIC 2015](#) with the [Zaven Khachaturian Award](#) for his achievement in advancing the field of Alzheimer's disease science.

A [press release](#) from the Alzheimer's Association notes that "Dr. Nixon's pioneering research into the early brain changes associated with Alzheimer's disease, including the abnormal breakdown of proteins, has helped scientists better understand the process by which Alzheimer's develops and progresses. His research has helped identify new avenues for investigating potential Alzheimer's disease therapies."

WELCOME ABOARD



Janie Rathjen has joined NKI as our new Personnel Director. By way of introduction, she shared the following:

“I’ve held various positions with several agencies during my career as a state employee, starting with Department of Corrections at the Fishkill Correctional Facility; then to the NYS Attorney General’s Office with the NYS Department of Law at Helen Hayes Hospital; Taconic DDSO; and most recently, Hudson Valley DDSO with the Office for People with Developmental Disabilities.

I’ve lived in the Hudson Valley most of my life and currently reside in Cold Spring. I enjoy spending time outdoors and getting together with my children and grandchildren. I am intrigued by NKI’s mission, accomplishments, and the on-going research work that is done here. Thanks for the warm welcome, and I look forward to meeting everyone!”

Return to the Old Country

In May, **Abel Lajtha, PhD** (Neurochemistry) returned to Budapest to give a speech as the **distinguished guest** during the commemoration of the 70th anniversary of the Biochemical Institute of the Medical School. The Institute was established in 1945, just after the war, by the most famous Hungarian scientist, Nobel Prize winner Albert Szent-Gyorgyi. Dr. Lajtha is the only living person

who joined Szent-Gyorgyi when he reorganized the Institute in 1945. Throughout his career, Dr. Lajtha’s Center for Neurochemistry often collaborated with the Budapest Institute.



Abel Lajtha (left) with close, and lifelong, friends from college, in 1941.


Not long after that, Dr. Lajtha visited Budapest again (and gave another speech), this time for the **dedication of a statue** in the middle of Budapest of his father, Laszlo Lajtha, a celebrated Hungarian composer. The ceremony took place on June 30th, Laszlo’s birthday. The statue is located near the Lajtha family house, in a garden where outdoor concerts are held. As an anti-Communist, Laszlo Lajtha was neglected during that regime.





Joseph LeDoux, PhD, Director of the [Emotional Brain Institute](#) (EBI), was interviewed on The Leonard Lopate Show in a segment titled “[How the brain processes anxiety](#)”.

This interview coincided with the release of Dr. LeDoux’s latest book, [Anxious: Using the Brain to Understand and Treat Fear and Anxiety](#) (Viking). *Anxious* received a [glowing review](#) in *Nature*.



The [June issue](#) of *OMH News* includes a contribution on the “Role of Culture in Recovery: A Peer Perspective” (page 3). This article was coauthored by **Jennifer Hernandez, MPA**, and **Adriana Joseph, MPH**, of NKI’s [Center of Excellence in Culturally Competent Mental Health](#).

In Memoriam

Robert “Chip” Durrie, who spent about 15 years at NKI doing neurochemical and neurobiological research, passed away on June 19th. Dr. Durrie retired to Wisconsin in 2000.

Steve DeRosa (Dementia Research) wants you to know that “We play soccer on Fridays from 5:00 until 6-6:30 on the field directly in front of the main entrance of NKI. It’s very informal, we play just for fun. If anyone would like to join us, please let me know and I will include you in our email list.”

PUBLICATIONS OF NOTE



The latest results from **Ralph Nixon’s lab** (Center for Dementia Research) appear online in *Molecular Psychiatry*. The article is open access. A [press release](#) explains the significance of this research.

Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini A, Rigoglioso A, Jiang Y, Nixon RA. [Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease](#). *Mol Psychiatry*. 2015 Jul 21.

Also recently published online in this journal is a connectome-wide association study coauthored by **Cameron Craddock** and **Michael Milham** (Center for Biomedical Imaging and Neuromodulation). This paper was noted on the Brain & Behavior Research Foundation’s [Discoveries blog](#).

Satterthwaite TD, Vandekar SN, Wolf DH, Bassett DS, Ruparel K, Shehzad Z, Craddock RC, Shinohara RT, Moore TM, Gennatas ED, Jackson C, Roalf DR, Milham MP, Calkins ME, Hakonarson H, Gur RC, Gur RE. [Connectome-wide network analysis of youth with Psychosis-Spectrum symptoms](#). *Mol Psychiatry*. 2015 Jun 2.



This review by **Xavier Castellanos** (Child & Adolescent Psychiatry) and Argelinda Baroni appears in a theme issue on cognitive enhancement.

Baroni A, Castellanos FX. [Stimulants, cognition and ADHD](#). *Current Opinion in Behavioral Sciences* 2015;4:109-14.



Crystal Lewis, the new head of Social Solutions and Services Research, is the first author of this study of a pharmacy intervention to decrease HIV risk among injection drug users.

Lewis CF, Rivera AV, Crawford ND, DeCuir J, Amesty S. [Pharmacy-randomized intervention delivering HIV prevention services during the syringe sale to people who inject drugs in New York City](#). *Drug Alcohol Depend*. 2015 Jun 10.



Joshua Kantrowitz (Schizophrenia Research) is the first author of this letter reporting on a small study attempting to improve response maintenance after ketamine treatment.

Kantrowitz JT, Halberstam B, Gangwisch J. [Single-Dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression](#). *J Clin Psychiatry*. 2015 Jun; 76(6):737-8.



Deputy Director **Antonio Convit**, along with NKI and NYU colleagues, report on the outcomes of the **BODY Project** in the *Journal of Community Health*.

Sweat V, Bruzzese JM, Fierman A, Mangone A, Siegel C, Laska E, Convit A. [Outcomes of The BODY Project: A Program to Halt Obesity and Its Medical Consequences in High School Students](#). *J Community Health*. 2015 May 23.



The latest publication from the lab of **Mariko Saito** (Neurochemistry), with **Mitsuo Saito**, **Maria Hui**, **Kurt Masiello**, and others, appears online in the *Journal of Lipid Research*.

Saito M, Wu G, Hui M, Masiello K, Dobrenis K, Ledeen RW, Saito M. [Ganglioside accumulation in glia during neurodegeneration and glial activation in the developing brain: Comparison between wild-type and GM2/GD2 synthase knock-out mice](#). *J Lipid Res*. 2015 Jun 10.

The Journal of Neuroscience

Hardly a month goes by without an NKI paper in *The Journal of Neuroscience*. The most recent is this one by **John Foxe** and colleagues.

Mercier MR, Molholm S, Fiebelkorn IC, Butler JS, Schwartz TH, Foxe JJ. [Neuro-oscillatory phase alignment drives speeded multisensory response times: an electro-corticographic investigation](#). *J Neurosci*. 2015 Jun 3; 35(22):8546-57.

Translational Psychiatry

The latest paper by **Latha Devi** and **Masuo Ohno** (Dementia Research) appears online in the open access journal *Translational Psychiatry*.

Devi L, Ohno M. [TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting \$\beta\$ -amyloidosis in 5XFAD mice](#). *Transl Psychiatry*. 2015 May 5;5:e562.

PSYCHOLOGICAL MEDICINE

Daniel Javitt, along with **Pamela Butler** and others, report on emotion recognition deficits in patients at high risk for schizophrenia. This paper was selected for inclusion and comment in *Journal Watch Psychiatry*.

Corcoran CM, Keilp JG, Kayser J, Klim C, Butler PD, Bruder GE, Gur RC, Javitt DC. [Emotion recognition deficits as predictors of transition in individuals at clinical high risk for schizophrenia: a neurodevelopmental perspective](#). *Psychol Med*. 2015 Jun 4:1-15.

Biological Psychiatry

A Journal of Psychiatric Neuroscience and Therapeutics

This paper by **Elizabeth Phelps** and **Joseph LeDoux** (Emotional Brain Institute) and NYU colleagues, was published in the August 1st print issue of *Biological Psychiatry*, on the theme of "Extinction and Posttraumatic Stress Disorder Treatment". *Psychiatric News* [reported on the research](#).

Dunsmoor JE, Campese VD, Ceceli AO, LeDoux JE, Phelps EA. [Novelty-Facilitated Extinction: Providing a Novel Outcome in Place of an Expected Threat Diminishes Recovery of Defensive Responses](#). *Biol Psychiatry*. 2015 Aug 1;78(3):203-9.



Pál Czobor, along with former NKI investigators Les Citrome and Jan Volavka, published this meta-analysis in *European Neuropsychopharmacology*.

Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. [Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies](#). *Eur Neuropsychopharmacol*. 2015 Apr 30.



In the new open access journal *Neuroscience Communications*, **Morris Baslow** proposes an answer to a question posed by Joseph Coyle in a [1997 paper](#).

Baslow MH. [An answer to "The Nagging Question of the Function of N-Acetylaspartylglutamate"](#). *Neuroscience Communications* 2015;2:e844.

The NKI librarian is always available to assist with literature searching, citation searching (Web of Science, Scopus), bibliographic reference management, and the like. When you have any information needs, or questions about available resources, don't hesitate to turn to us.

The library still offers a comfortable, quiet space for reading, work, and small meetings. And we now have Wi-Fi. Just ask the library staff for the password.

You can [link to the NKI Library's website](#) from myNKI. The Library site includes quick links to the NYU Health Sciences Library and to the New York State Library, as well as links to NKI's own library resources ([journal finder](#), [online catalog](#), [PsychiatryOnline](#), etc.). Remote access is available using NKI's VPN.

INFO UPDATE



On June 16th, the 25 millionth journal citation was added to PubMed.

A new initiative called [PubMed Labs](#) aims to involve the user community in creating innovative products, through experimentation, learning, and conversation. The first of these is a [new feature](#) (utilizing anonymous click data) designed to help you find related articles quickly. Now, some PubMed abstracts have a link called “Articles frequently viewed together”. Look for this link in the right column under “Related Information”. [SmartBLAST](#), an enhancement to protein BLAST, is another new, experimental feature.



A recent blog post (“[Early BRAIN Breakthroughs](#)”) by NIMH Director Tom Insel, MD highlights some early fruits of the [BRAIN Initiative](#).

The New York Times Magazine

The New York Times Magazine recently published a special mental health theme issue. It features articles including “[Can the Bacteria in Your Gut Explain Your Mood?](#)”, “[I Don’t Believe in God, but I Believe in Lithium](#)”, “[Why I’m Afraid of Therapy](#)”, and “[Confessions of a Seduction Addict](#)”.

Nature now offers a free daily news alert. “[Sign up now](#) to receive your essential wrap-up of the major stories across the world of science”.



The 2014 edition of [Health, United States](#) – presenting an annual overview of national trends in health statistics – was released in May. The 2014 edition includes a [Special Feature on Adults Aged 55–64](#).

An article in the June issue of the *Harvard Business Review* suggests ways of “[Conquering Digital Distraction](#)”. Here you will find different strategies offered by a psychologist and a technologist.

The Journal of Clinical Psychiatry offers a monthly Publisher’s Podcast – an audio summary of topics in the latest issue. You can listen and subscribe [here](#).

DEPARTMENT OF WONDER



The Rockefeller Foundation–Lancet Commission on planetary health has published its final report, entitled “[Safeguarding human health in the Anthropocene epoch](#)”, which concludes that:

“we have been mortgaging the health of future generations to realise economic and development gains in the present. By unsustainably exploiting nature’s resources, human civilisation has flourished but now risks substantial health effects from the degradation of nature’s life support systems in the future.”

Accompanying the report is this succinct [infographic](#).

The New York Times

The New York Times recently [reported](#) on a rare condition, now named aphantasia, in which people are unable to conjure mental images. In other words, they lack a “mind’s eye”. [Preliminary research](#) on the subject, by Adam Zeman and colleagues, appears in the journal *Cortex*.



Google Earth celebrated its 10th birthday at the end of June. See the [Google Blog](#) for an overview of its past as well as its latest features, and check out [Earth View](#) for some amazing images.

NKI ON THE ROAD



Nunzio Pomara, MD (Geriatric Psychiatry), with NKI coauthors including **Babak Ardekani, Alvin Bachman, Jay Nierenberg, Eva Petkova, Chelsea Reichert, and John Sidtis**, contributed to four posters at the [2015 Alzheimer’s Association International Conference](#) held in Washington, DC, from July 18-23. The poster titles were:

- Predictors of Cognitive Decline in Elderly Depressives
- A Comparison of Hippocampal Volume and Integrity: Which Is the Better Predictor of Cognitive Decline?
- The Association of Output Order and Variability in Free Recall with Cognitive Ability and Hippocampal Volume in Elderly Individuals
- Is Hippocampal Size Associated with Primacy Recall Performance in Amnesic Mild Cognitive Impairment?

Dr. Pomara was the presenting author for the first two.

For news about the award received by **Dr. Ralph Nixon** at the AAIC this year, see the KUDOS section on page 3.



The 2015 annual meeting of the [American Society of Clinical Psychopharmacology](#) took place in Miami in June, with contributions by **Jean-Pierre Lindenmayer, MD** and **Anzalee Khan, PhD** (Manhattan Psychiatric Center) and **Vilma Gabbay, MD** (Child & Adolescent Psychiatry).

Dr. Lindenmayer chaired a session on “Long Acting Injectables in the Treatment of Schizophrenia: Missed Opportunities and Challenges”.

Dr. Khan gave two session presentations, on “Individualizing and Integrating Measurement Tools for Social Cognition” and “Measuring Statistically and Clinically Meaningful Change in Clinical Trials: Moving away from Percent Change and Arbitrary Changes in Scores”. She also presented posters titled “Scientific Brain Training Programs on Cognition, Social Cognition and Functioning: Comparison of Cognitive Remediation Programs in Severe Mental Illness” and “Psychometric Properties of the Dynamic Social Cognition Battery (DSCB) in Patients with Severe Mental Illness”.

Dr. Gabbay contributed to two posters, on “Brain Metabolite Abnormalities in Depressed Adolescents” and “The Role of the Kynurenine Pathway in Suicidality in Adolescent Major Depressive Disorder”. This research was covered by Medscape ([“New Biomarker May Predict Suicide”](#)).

Abstracts for the [oral sessions](#) and the [posters](#) are online.



Vinod Yaragudri, PhD (Analytical Psychopharmacology) presented a poster entitled “CB1 receptor modulates neuropeptide Y expression through epigenetic changes and reduces alcohol consumption” (Vinod KY, Sakharkar AJ, Zhang H, Vemuri K, Makriyannis A, Hungund BL, Pandey SC) at the [Research Society on Alcoholism Scientific Meeting](#) in San Antonio, TX.

UPCOMING EVENTS AND SEMINARS

Statewide Satellite Grand Rounds



Synthetic Cannabinoids: An Emerging Epidemic

Presenter – Charles Morgan, MD
Acting Medical Director, NYS OASAS

Panelist – Mark Sorensen, MD
Clinical Director, Creedmoor Psychiatric Center

Wednesday, September 16th at 1:00 pm

The New York State Office of Mental Health (OMH) hosts a monthly interactive video broadcast covering the latest research, technology and treatment implementation in the fields of psychiatry and psychology. These programs are recorded, and the archived Statewide Grand Rounds programs can be viewed by OMH employees [on the OMH intranet](#). Anyone can view the programs [on the OMH website](#).

NKI PUBLICATIONS UPDATE

Below is a list of references that have been added to the NKI publications database since the previous update. The full database contains over 5,000 items dating back to 1995, and can be searched from the [NKI web site](#).

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. *J Clin Psychiatry*. 2015 May; 76(5): 554-61.

Baslow MH, Guilfoyle DN. N-acetyl-L-histidine, a Prominent Biomolecule in Brain and Eye of Poikilothermic Vertebrates. *Biomolecules*. 2015 Apr 24;5(2):635-46.

Berg A, Byrne R, Coffey BJ. Neuroleptic Malignant Syndrome in a Boy with NMDA Receptor Encephalitis. *J Child Adolesc Psychopharmacol*. 2015 May;25(4):368-71.

Ciarleglio A, Petkova E, Ogden RT, Tarpey T. Treatment decisions based on scalar and functional baseline covariates. *Biometrics*. 2015 Jun 25.

Corcoran CM, Keilp JG, Kayser J, Klim C, Butler PD, Bruder GE, Gur RC, Javitt DC. Emotion recognition deficits as predictors of transition in individuals at clinical high risk for schizophrenia: a neurodevelopmental perspective. *Psychol Med*. 2015 Jun 4:1-15.

Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. *Eur Neuropsychopharmacol*. 2015 Apr 30.

Devi L, Ohno M. TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β -amyloidosis in 5XFAD mice. *Transl Psychiatry*. 2015 May 5;5:e562.

Haghighi F, Galfalvy H, Chen S, Huang YY, Cooper TB, Burke AK, Oquendo MA, Mann JJ, Sublette ME. DNA methylation perturbations in genes involved in polyunsaturated Fatty Acid biosynthesis associated with depression and suicide risk. *Front Neurol*. 2015 Apr 28;6:92.

Hillyard SA, Störmer VS, Feng W, Martinez A, McDonald JJ. Cross-modal orienting of visual attention. *Neuropsychologia*. 2015 Jun 11.

Horwitz SM, Storfer-Isser A, Kerker BD, Lilo E, Leibovitz A, St John N, Shaw RJ. A model for the development of mothers' perceived vulnerability of preterm infants. *J Dev Behav Pediatr*. 2015 Jun; 36(5):371-80.

Kantrowitz JT, Halberstam B, Gangwisch J. Single-Dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. *J Clin Psychiatry*. 2015 Jun;76(6):737-8.

Kucharsky Hiess R, Alter R, Sojoudi S, Ardekani BA, Kuzniecky R, Pardoe HR. Corpus Callosum Area and Brain Volume in Autism Spectrum Disorder: Quantitative Analysis of Structural MRI from the ABIDE Database. *J Autism Dev Disord*. 2015 Jun 5.

Lewis CF, Rivera AV, Crawford ND, DeCuir J, Amesty S. Pharmacy-randomized intervention delivering HIV prevention services during the syringe sale to people who inject drugs in New York City. *Drug Alcohol Depend*. 2015 Jun 10.

Mahler J, Morales-Corraliza J, Stolz J, Skodras A, Radde R, Duma CC, Eisele YS, Mazzella MJ, Wong H, Klunk WE, Nilsson KP, Staufenbiel M, Mathews PM, Jucker M, Wegenast-Braun BM. Endogenous murine $A\beta$ increases amyloid deposition in APP23 but not in APPPS1 transgenic mice. *Neurobiol Aging*. 2015 Jul;36(7):2241-7.

Markowitz JC, Meehan KB, Petkova E, Zhao Y, Van Meter PE, Neria Y, Pessin H, Nazia Y. Treatment preferences of psychotherapy patients with chronic PTSD. *J Clin Psychiatry*. 2015 Jun 9.

Marshall O, Uh J, Lurie D, Lu H, Milham MP, Ge Y. The influence of mild carbon dioxide on brain functional homotopy using resting-state fMRI. *Hum Brain Mapp*. 2015 Jul 2.

Mercier MR, Molholm S, Fiebelkorn IC, Butler JS, Schwartz TH, Foxe JJ. Neuro-oscillatory phase alignment drives speeded multisensory response times: an electro-corticographic investigation. *J Neurosci*. 2015 Jun 3;35(22):8546-57.

Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. *Innov Clin Neurosci*. 2015 Mar-Apr;12(3-4):26S-40S.

Noy N, Bickel S, Zion-Golumbic E, Harel M, Golan T, Davidesco I, Schevon CA, McKhann GM, Goodman RR, Schroeder CE, Mehta AD, Malachand R.

Intracranial recordings reveal transient response dynamics during information maintenance in human cerebral cortex. *Hum Brain Mapp.* 2015 Jul 3.

Reiss PT. Cross-validation and hypothesis testing in neuroimaging: An ironic comment on the exchange between Friston and Lindquist et al. *Neuroimage.* 2015 Aug 1;116:248-54.

Rice T, Coffey BJ. Pharmacotherapeutic Considerations in the Treatment of an Adolescent with Anorexia Nervosa and Obsessive Compulsive Disorder. *J Child Adolesc Psychopharmacol.* 2015 Jun;25(5):444-7.

Rodriguez CI, Kegeles LS, Levinson A, Ogden RT, Mao X, Milak MS, Vermes D, Xie S, Hunter L, Flood P, Moore H, Shungu DC, Simpson HB. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. *Psychiatry Res.* 2015 Jun 6.

Ross LA, Del Bene VA, Molholm S, Frey HP, Foxe JJ. Sex differences in multisensory speech processing in both typically developing children and those on the autism spectrum. *Front Neurosci.* 2015 May 27;9:185.

Réus GZ, Jansen K, Titus S, Carvalho AF, Gabbay V, Quevedo J. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. *J Psychiatr Res.* 2015 May 19.

Saito M, Wu G, Hui M, Masiello K, Dobrenis K, Ledeen RW, Saito M. Ganglioside accumulation in glia during neurodegeneration and glial activation in the developing brain: Comparison between wild-type and GM2/GD2 synthase knock-out mice. *J Lipid Res.* 2015 Jun 10.

Satterthwaite TD, Vandekar SN, Wolf DH, Bassett DS, Ruparel K, Shehzad Z, Craddock RC, Shinohara RT, Moore TM, Gennatas ED, Jackson C, Roalf DR, Milham MP, Calkins ME, Hakonarson H, Gur RC, Gur RE. Connectome-wide network analysis of

youth with Psychosis-Spectrum symptoms. *Mol Psychiatry.* 2015 Jun 2.

Schneider NY, Datiche F, Wilson DA, Gigot V, Thomas-Danguin T, Ferreira G, Coureaud G. Brain processing of a configural vs elemental odor mixture in the newborn rabbit. *Brain Struct Funct.* 2015 May 16.

Sokol-Hessner P, Lackovic SF, Tobe RH, Camerer CF, Leventhal BL, Phelps EA. Determinants of Propranolol's Selective Effect on Loss Aversion. *Psychol Sci.* 2015 Jun 10.

Sweat V, Bruzzese JM, Fierman A, Mangone A, Siegel C, Laska E, Convit A. Outcomes of The BODY Project: A Program to Halt Obesity and Its Medical Consequences in High School Students. *J Community Health.* 2015 May 23.

Xiao F, Hrabec J, Hrabetova S. Anomalous extracellular diffusion in rat cerebellum. *Biophys J.* 2015 May 5;108(9):2384-95.

Baroni A, Castellanos FX. Stimulants, cognition and ADHD. *Current Opinion in Behavioral Sciences* 2015;4:109-14.

Baslow MH. An answer to "The Nagging Question of the Function of N-Acetylaspartylglutamate". *Neuroscience Communications* 2015;2:e844.

Bruno D, Grothe MJ, Nierenberg J, Teipel SJ, Zetterberg H, Blennow K et al. The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 2015;1(1):81-6.

Freudenreich O, Goff DC, Henderson DC. Antipsychotic drugs. In: Stern TA, Fava M, Wilens TE, Rosenbaum JF, editors. *Massachusetts General Hospital Psychopharmacology and Neurotherapeutics.* Elsevier Health Sciences; 2015. p. 72-85.

Javitt DC. Meeting overview: Sensory perception and schizophrenia, Lausanne, Switzerland June 31–July 1, 2014. *Schizophrenia Research: Cognition* 2015;2(2):42-5.

Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. *Lancet Psychiatry* 2015;2(5):403-12.

Khan Rhodes A, Farrell M, Rothman B. Cognitive effects of benzodiazepine-use in subjects with mild to severe Alzheimer's disease and related dementia. *Neuro-degenerative Diseases* 15[Suppl. 1], 1825. [Abstract]

Knuth KH, Habeck M, Malakar NK, Mubeen AM, Placek B. Bayesian evidence and model selection. *Digital Signal Processing* 2015.

Levy E, Perez-Gonzalez R. Neuroprotective regulation of exosome secretion by cystatin. *Neuro-degenerative Diseases* 15[Suppl. 1], 76. 2015. [Abstract]

Lucic L, Daiute C, Khan A. Narrative exploration of social cognition in adults hospitalized due to symptoms of schizophrenia. *European Psychiatry* 2015;30(Suppl. 1):1282. [Abstract]

Lucic L, Khan A, Liharska L, Rothman B. What can we learn about psycho-social functioning of individuals diagnosed with schizophrenia from standardized patients? *European Psychiatry* 2015; 30(Suppl. 1):1268. [Abstract]

Mendoza S, Hansen H. The impact of opioid prescriber surveillance on doctor-patient relationships and drug markets. *American Journal on Addictions* 24[1], 77. 2015. [Abstract]

Morales-Corraliza J, Wong H, Mazzella M, Che S, Wagner J, Hemby S et al. Decreased hippocampal neprilysin in a type 1 diabetes primate model leads

to an increase in Abeta levels. *Neuro-degenerative Diseases* 15[Suppl. 1], 18. 2015. [Abstract]

Pandey AK, Ardekani BA, Elahi S, Kamarajan C, Chorlian DB, Stimus A et al. An MRI study of structural brain abnormalities in alcoholism. *Alcoholism: Clinical & Experimental Research* 39[Suppl. S1], 178A. 2015. [Abstract]

Perez-Gonzalez R, Levy E. Amyloid-beta associated brain-derived exosomes promote amyloid seeding in a mouse model of amyloidosis. *Neuro-degenerative Diseases* 15[Suppl. 1], 515. 2015. [Abstract]

Saito M, Smiley JF, Macielo K, Sadrian B, Vadasz C, Saito M et al. The long-lasting effects of early ethanol exposure on parvalbuminpositive interneurons. *Alcoholism: Clinical & Experimental Research* 39[Suppl. S1], 102A. 2015. [Abstract]

Sweeney C, Warner CM, Brice C, Stewart C, Ryan J, Loeb KL et al. Identification of Social Anxiety in Schools: the Utility of a Two-Step Screening Process. *Contemporary School Psychology* 2015.

Teipel SJ, Bruno D, Grothe MJ, Nierenberg J, Pomara N. Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 2015;1(2):216-9.

Vinod KY, Sakharkar AJ, Zhang H, Vemuri K, Makriyannis A, Hungund BL et al. CB1 receptor modulates neuropeptide Y expression through epigenetic changes and reduces alcohol consumption. *Alcoholism: Clinical & Experimental Research* 39[Suppl. S1], 189A. 2015. [Abstract]

Warner CM, Colognori D, Brice C, Sanchez A. School-based interventions for adolescents with social anxiety disorder. In: Ranta K, La Greca AM, Garcia-Lopez LJ, Marttunen M, editors. *Social anxiety and phobia in adolescents: development, manifestation and intervention strategies*. Springer; 2015. p. 271-87.